Effect of oral urea ingestion on growth hormone levels in healthy adults - a secondary analysis of a randomized, double-blind, placebo-controlled cross-over trial.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

Available stimulation tests for growth hormone (GH) deficiency are burdensome or require intravenous access, highlighting the need for accessible, oral options.

In this analysis, the researchers investigated the effect of oral urea on GH levels.

Who Took Part

The age groups tagged for this paper are young adults and adults, both men and women.

This is a secondary analysis of a double-blind, randomized, placebo-controlled cross-over trial in healthy adults.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.

In the crossover set-up each of the participants took both Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison in turn, acting as their own control.

Serum GH was measured at baseline, 60 and 120 min.

The main outcome was the difference in absolute GH levels after placebo and urea intake.

What Was Measured

Topics PubMed links to this paper include Urea, Human Growth Hormone and Growth Hormone.

The authors tagged it with the keywords Anterior pituitary stimulation test and Growth hormone deficiency.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2025 (Pituitary), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.